COMMUNIQUÉS West-GlobeNewswire

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
12/06/2018
CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today [...]
Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
12/06/2018
- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C., June 12, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a [...]
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
12/06/2018
The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. ( [...]
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
12/06/2018
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to [...]
Radient Technologies Inc. Files FDA Submission for Reducing Nicotine in Tobacco
12/06/2018
EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has made a submission to the U.S. Food and Drug Administration [...]
Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
12/06/2018
PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI) HAIFA, Israel, June 12, 2018 [...]
Transactions in relation to share buyback program
12/06/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications
12/06/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
First Medical Patent Issued for the Oculenz™ Augmented Reality Glasses
12/06/2018
Ocutrx™ AR Glasses Garners First Medical Patent for Restoring Functional Sight to Patients with Visual Field Deficits IRVINE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California based [...]
William Demant Holding A/S: Investor news - agenda and presentations for Capital Markets Day 2018
12/06/2018
Investor news 12 June 2018 Agenda and presentations for Capital Markets Day 2018 William Demant Holding A/S will today host its Capital Markets Day 2018 in London with the following agenda: 09:30 Registration 10:00 [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
12/06/2018
FIT Biotech Oy Company release June 12, 2018 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]
Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
12/06/2018
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Sentia announced today the appointment of Dr. Yvette Taché, Ph.D. as Chair of the Scientific Advisory Board. Dr. Taché, Ph.D. is a Distinguished Professor in the Vatche and [...]
Solon Eiendom ASA : Primary insider notification
12/06/2018
(Oslo, Norway, June 11, 2018) UFI AS has today bought 15.145 shares in Solon Eiendom ASA at a price of NOK 30.027 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]
Shire plc : Rule 2.9 Announcement
12/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 June 2018 Shire [...]
FIT Biotech Oy: First EHVA clinical trial authorization granted for testing FIT-06
12/06/2018
FIT Biotech Oy Company release 12.6.2018 at 8:30 AM EET First EHVA clinical trial authorization granted for testing FIT-06 FIT Biotech Oy ("Company", FITBIO: FN Finland) today announced that the Swiss medical [...]
European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding
12/06/2018
Amsterdam, The Netherlands - 12 June 2018 Esperite N.V. (Euronext: ESP, " Esperite " or the " Group ") announces today the issuance to European Select Growth Opportunities Fund (the " Investor " or " ESGO ") of the 19th [...]
Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2018
12/06/2018
Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2018 Amsterdam, the Netherlands, San Diego, CA, USA and Holzgerlingen, Germany , June 12, 2018 , 01:00 a.m. EST -- Curetis N.V. (the " [...]
Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON
12/06/2018
Pratteln, Switzerland, June 12, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the Korean Ministry of Food and Drug Safety (MFDS) has accepted for review Santhera's new drug application (NDA) for Raxone® ( [...]
argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018
12/06/2018
June 12, 2 018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Pages